Improving Health, Health Care and Quality of Life
DENVER, Dec. 18, 2019 /PRNewswire/ -- DaVita Kidney Care today announced Dr. Jeffrey Giullian as chief medical officer (CMO). Dr. Giullian has most recently led clinical quality and safety efforts as CMO for DaVita Hospital Services, and he will continue in that role in the interim, in addition to becoming CMO for DaVita Kidney Care.
"Dr. Giullian is a dynamic, visionary leader who will push the boundaries on the positive impact we can make on kidney health," said Javier Rodriguez, CEO for DaVita Inc. "We have great confidence that he'll continue to build on the clinical foundation our team of physician leaders has built for 20 years."
Since joining DaVita in 2016, Dr. Giullian has supported and grown DaVita's clinical capabilities in multiple capacities, including serving as national group medical director and playing an active role in organizing local clinical operations response efforts during natural disasters.
Dr. Giullian succeeds Dr. Allen R. Nissenson, who will be stepping down after serving as DaVita's CMO for more than 11 years.
"I'm honored to follow Dr. Nissenson as CMO and I have deep gratitude for the impact he has made on kidney care," said Dr. Giullian. "I am committed to partnering with our physicians to provide holistic, integrated care for patients in all phases of kidney disease. Together, I believe we can forge a future of innovation and reduce the global burden of kidney failure."
Dr. Giullian has been active in the Renal Physicians Association (RPA) as chairman of the Healthcare Payment Committee and member of the RPA's team of advisors to the American Medical Association Relative Value Units Utilization Committee. He trained in nephrology and transplantation at Vanderbilt University and received his MBA from the University of Colorado at Denver.
To learn more about DaVita and its leadership, visit DaVita.com/About.
About DaVita Inc.
DaVita (NYSE: DVA) is a Fortune 500® health care provider focused on transforming care delivery to improve quality of life for patients globally. The company is the largest provider of kidney care services in the U.S. and has been a leader in clinical quality and innovation for 20 years. Through DaVita Kidney Care, the company treats patients with chronic kidney failure and end stage renal disease. DaVita is committed to bold, patient-centric care models, implementing the latest technologies and moving toward integrated care offerings for all. Through these efforts, DaVita has also become the largest provider of home dialysis in the country. As of September 30, 2019, DaVita served 204,900 patients at 2,736 outpatient dialysis centers in the United States. The company also operated 249 outpatient dialysis centers in nine countries worldwide. DaVita has reduced hospitalizations, improved mortality, and worked collaboratively to propel the kidney care industry to adopt an equitable and high-quality standard of care for all patients, everywhere. To learn more, visit DaVita.com/About.
Certain statements in this press release are forward-looking statements that are subject to risks and uncertainties. These forward-looking statements are based on management's current expectations. Various important factors could cause actual results to differ materially, including the risks identified in our U.S. Securities and Exchange Commission filings. DaVita disclaims any obligation to update any forward-looking statement contained in this press release.
Media Contact Information
SOURCE DaVita Kidney Care